Bern - Berna Biotech will be bought by the Dutch biotech company Crucell NV. Shareholders of both companies voted in favour of the deal valued at some Euro390 million after Novartis declined to make a counter-offer to Crucell's bid (see left). In contrast to the Dutch company, Novartis would have added an attractive cash component to the share deal. Crucell, which has never posted a profit, intends to merge the two firms to make a larger vaccines player. As a result, Berna's shareholders will own only 27% of the new company though Berna's revenues are six times higher. CEO Kuno Sommer explained that the smaller of the two companies is taking over the larger because of Crucell's much higher value at the stock exchange.